文献速递特殊人群用药

基于PBPK-PD模型优化妊娠期高血压甲基多巴给药方案

Determining the Optimal Dosing of Methyldopa in Pregnancy-Induced Hypertension Using PBPK-PD Modeling.
PubMed 文献 · Clin Pharmacokinet · 2025-06-14

本研究采用PK-Sim、MoBi和MATLAB构建并验证了妊娠特异性甲基多巴PBPK-PD模型,模拟妊娠各阶段平均动脉压反应并计算最优剂量。模型显示妊娠期PST活性无显著变化,PK/PD波动不显著;MAP≤130 mmHg时500 mg为最优方案,MAP>130 mmHg需联合其他降压药,且因起效延迟前48小时应联用其他降压药。

要点

  • MAP≤130 mmHg的妊娠期高血压患者,甲基多巴最优剂量为500 mg。
  • MAP>130 mmHg时,建议加用其他降压药物。
  • 甲基多巴起效延迟,初始48小时应联合其他降压药。

核心结论

  • 所建PBPK-PD模型可用于优化甲基多巴治疗并支持妊娠期高血压个体化治疗策略。

研究设计与样本

  • 使用PK-Sim、MoBi和MATLAB构建妊娠特异性甲基多巴PBPK-PD模型,参数来自文献。
  • 建模步骤包括:构建并验证非妊娠个体PBPK模型(含肾清除、血清清除和酶清除);扩展为妊娠PBPK模型并验证口服给药;用最大效应模型构建PK/PD模型;整合为统一PBPK-PD模型。
  • 模型用于模拟妊娠不同阶段的平均动脉压反应并计算最优给药方案。

主要发现

  • 模型验证结果拟合良好,参数适当。
  • 妊娠模型显示酚磺基转移酶(PST)活性在妊娠期间无显著变化。
  • 妊娠各阶段PBPK-PD模拟显示PK和PD有波动,但变化不特别显著。

关键数值与推荐

  • MAP≤130 mmHg的患者,500 mg为最优给药方案。
  • MAP>130 mmHg的患者,推荐加用其他降压药物。
  • 因起效延迟,甲基多巴应在最初48小时内与其他降压药联合使用。

临床怎么用

  • 临床可参考MAP水平选择甲基多巴剂量:MAP≤130 mmHg用500 mg,MAP>130 mmHg联合其他降压药。
  • 开始甲基多巴治疗的前48小时应联用其他降压药以覆盖起效延迟期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy-induced hypertension is a significant risk factor for adverse maternal and fetal outcomes, with methyldopa being a commonly prescribed antihypertensive for its safety profile. However, the physiological changes during pregnancy may alter the pharmacokinetics (PK) and pharmacodynamics (PD) of methyldopa, complicating the establishment of optimal dosing regimens. OBJECTIVE: This study aims to develop and validate a pregnancy-specific physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) model for methyldopa to optimize dosing strategies and support individualized treatment plans for managing pregnancy-induced hypertension effectively. METHODS: The PBPK-PD model for methyldopa was developed using PK-Sim, MoBi, and MATLAB software, incorporating pregnancy-specific physiological parameters from the literature. The development process involved: (a) constructing and validating a PBPK model for non-pregnant individuals based on intravenous and oral administration, including renal clearance, serum clearance, and enzyme clearance; (b) extending the model to a pregnant PBPK model and validating it for oral administration; (c) constructing a PK/PD model using the maximum effect model; and (d) integrating the PBPK and PK/PD models to form a unified PBPK-PD model. This model was then used to simulate mean arterial pressure (MAP) responses across different stages of pregnancy. Finally, the optimal dosing regimen was calculated. RESULTS: The model verification results show a good fit, indicating that the parameters are appropriate. The pregnancy model indicated no significant change in phenol sulfotransferase (PST) activity during pregnancy. The physiologically based pharmacokinetic-pharmacodynamic simulations across different stages of pregnancy show fluctuations in both PK and PD; however, these variations are not particularly significant. Ultimately, the results indicate that 500 mg is the optimal dosing regimen for patients with MAP ≤ 130 mmHg. For MAP > 130 mmHg, additional antihypertensive medications are recommended. Due to its delayed onset, methyldopa should be combined with other antihypertensives during the first 48 hours. CONCLUSION: The PBPK-PD model developed in this study provides a valuable tool for optimizing methyldopa therapy, supporting personalized treatment strategies, and improving blood pressure management and maternal and fetal health outcomes in pregnancy-induced hypertension.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Liu X, Wang W, Zhu J, et al. Determining the Optimal Dosing of Methyldopa in Pregnancy-Induced Hypertension Using PBPK-PD Modeling. Clin Pharmacokinet. 2025. PMID: 40516012. doi:10.1007/s40262-025-01523-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。